Bodyport, a company building sensitive sensor technologies into a bathroom scale, secured an $11.2 million Series A round to develop a device that can help detect and manage heart disease by detecting cardiac signals and biomarkers through bare feet.
Boehringer Ingelheim Venture Fund (BIVF) led the round in the San Francisco-based startup, adding its capital to $4.6 million from previous investors including Playground Global and Initialized Capital.
The new round also support the launch of a “virtual cardiac clinic,” according to a release.
“We’re focused on changing the way patients and care teams manage heart disease,” said Corey Centen, co-founder and CEO. “By shifting the technology patients can access from a clinical setting to their own home, we are aiming to predict changes in health status before a hospital visit becomes necessary.”
Centen founded the company with fellow biomedical engineer Sarah Smith to make it easier to manage heart fai…